Kanya Rajangam

2022 - Senti Biosciences

In 2022, Kanya Rajangam earned a total compensation of $840.5K as Head of Research and Development and Chief Medical Officer at Senti Biosciences.

Compensation breakdown

Bonus$90,000
Non-Equity Incentive Plan$96,515
Option Awards$412,703
Salary$241,288
Total$840,506

Rajangam received $412.7K in option awards, accounting for 49% of the total pay in 2022.

Rajangam also received $90K in bonus, $96.5K in non-equity incentive plan and $241.3K in salary.

Rankings

In 2022, Kanya Rajangam's compensation ranked 3,337th out of 5,534 executives tracked by ExecPay. In other words, Rajangam earned more than 39.7% of executives.

ClassificationRankingPercentile
All
3,337
out of 5,534
40th
Division
Manufacturing
1,882
out of 3,000
37th
Major group
Chemicals And Allied Products
892
out of 1,350
34th
Industry group
Drugs
832
out of 1,253
34th
Industry
Biological Products, Except Diagnostic Substances
205
out of 287
29th
Source: SEC filing on April 28, 2023.

Rajangam's colleagues

We found two more compensation records of executives who worked with Kanya Rajangam at Senti Biosciences in 2022.

2022

Deborah Knobelman

Senti Biosciences

Chief Financial Officer

2022

Timothy MDPhD

Senti Biosciences

Chief Executive Officer

News

You may also like